Literature DB >> 23099237

TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes.

Jieyu Wang1, Xiaofei Ai, Robert Peter Gale, Zefeng Xu, Tiejun Qin, Liwei Fang, Hongli Zhang, Lijuan Pan, Naibo Hu, Yue Zhang, Zhijian Xiao.   

Abstract

Somatic mutations of epigenetic gene regulators are common in patients with myelodysplastic syndromes (MDS) and correlate with some clinical and laboratory features. We studied mutations in TET2, ASXL1 and EZH2 in 153 Chinese patients with MDS. TET2 mutations were detected in 35 patients (23%), ASXL1 in 33 patients (22%) and EZH2 in 8 (5%). ASXL1 mutations were associated with increased colony formation of BFU-E, CFU-E and CFU-GM (P-values, 0.049, 0.011 and 0.006). EZH2 mutations were common in patients with poor IPSS cytogenetics (P=0.001) and in patients in the IPSS intermediate-2/high-risk cohorts (P=0.06). In uni- but not multi-variate analyses, mutated TET2 was associated with longer survival (P=0.044) whereas EZH2 mutations were associated with an increased risk of transformation to acute myeloid leukemia (AML; P=0.039). These data suggest ASXL1 mutations might results in dominance of the mutant clone in Chinese with MDS whereas EZH2 mutations might predict an increased risk of transformation to AML.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23099237     DOI: 10.1016/j.leukres.2012.10.004

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  21 in total

1.  Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers.

Authors:  Lan Xu; Zhao-Hui Gu; Yang Li; Jin-Li Zhang; Chun-Kang Chang; Chun-Ming Pan; Jing-Yi Shi; Yang Shen; Bing Chen; Yue-Ying Wang; Lu Jiang; Jing Lu; Xin Xu; Jue-Ling Tan; Yu Chen; Sheng-Yue Wang; Xiao Li; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-21       Impact factor: 11.205

2.  Mutations of ASXL1 and TET2 in aplastic anemia.

Authors:  Jinbo Huang; Meili Ge; Shihong Lu; Jun Shi; Xingxin Li; Jizhou Zhang; Min Wang; Wei Yu; Yingqi Shao; Zhendong Huang; Jing Zhang; Neng Nie; Yizhou Zheng
Journal:  Haematologica       Date:  2015-01-16       Impact factor: 9.941

3.  Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals.

Authors:  Xudong Wu; Ida Holst Bekker-Jensen; Jesper Christensen; Kasper Dindler Rasmussen; Simone Sidoli; Yan Qi; Yu Kong; Xi Wang; Yajuan Cui; Zhijian Xiao; Guogang Xu; Kristine Williams; Juri Rappsilber; Casper Kaae Sønderby; Ole Winther; Ole N Jensen; Kristian Helin
Journal:  Cell Res       Date:  2015-10-16       Impact factor: 25.617

4.  Myelodysplasia: new approaches.

Authors:  Karen Seiter
Journal:  Curr Treat Options Oncol       Date:  2013-06

Review 5.  Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes.

Authors:  Diamantina Vasilatou; Sotirios G Papageorgiou; George Dimitriadis; Vasiliki Pappa
Journal:  Epigenetics       Date:  2013-05-09       Impact factor: 4.528

6.  Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.

Authors:  Lingyun Wu; Luxi Song; Lan Xu; Chunkang Chang; Feng Xu; Dong Wu; Qi He; Jiying Su; Liyu Zhou; Chao Xiao; Zheng Zhang; Youshan Zhao; Saijuan Chen; Xiao Li
Journal:  Tumour Biol       Date:  2015-10-28

7.  Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia.

Authors:  Yajuan Cui; Hongyan Tong; Xin Du; Bing Li; Robert Peter Gale; Tiejun Qin; Jinqin Liu; Zefeng Xu; Yue Zhang; Gang Huang; Jie Jin; Liwei Fang; Hongli Zhang; Lijuan Pan; Naibo Hu; Shiqiang Qu; Zhijian Xiao
Journal:  Exp Hematol Oncol       Date:  2015-05-20

Review 8.  Potential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome.

Authors:  Ting Zhou; Peishuai Chen; Jian Gu; Alexander J R Bishop; Linda M Scott; Paul Hasty; Vivienne I Rebel
Journal:  Int J Mol Sci       Date:  2015-01-05       Impact factor: 5.923

9.  Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain.

Authors:  Stephen Antonysamy; Bradley Condon; Zhanna Druzina; Jeffrey B Bonanno; Tarun Gheyi; Feiyu Zhang; Iain MacEwan; Aiping Zhang; Sheela Ashok; Logan Rodgers; Marijane Russell; John Gately Luz
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

10.  Submicroscopic deletion of 5q involving tumor suppressor genes (CTNNA1, HSPA9) and copy neutral loss of heterozygosity associated with TET2 and EZH2 mutations in a case of MDS with normal chromosome and FISH results.

Authors:  Morteza Hemmat; Weina Chen; Arturo Anguiano; Mohammed El Naggar; Frederick K Racke; Dan Jones; Yongbao Wang; Charles M Strom; Karl Chang; Fatih Z Boyar
Journal:  Mol Cytogenet       Date:  2014-05-27       Impact factor: 2.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.